Filter
193
Filtered Results: 193
Text search:
monoclonal
antibodies
Featured
Recommendations
31
New Publications
34
Language
Document type
No document type
79
Guidelines
47
Studies & Reports
28
Manuals
15
Fact sheets
10
Strategic & Response Plan
6
Resource Platforms
3
Training Material
2
Infographics
2
Situation Updates
1
Countries / Regions
India
14
Global
13
South Africa
7
Germany
4
Latin America and the Carribbean
4
Congo, Democratic Republic of
3
Philippines
3
Syria
3
Venezuela
3
Nigeria
2
Mali
2
Niger
2
Pakistan
2
Afghanistan
2
West and Central Africa
2
Middle East and North Africa
2
Africa
2
Russia
2
France
2
Spain
2
Burkina Faso
1
Sierra Leone
1
Liberia
1
Senegal
1
Côte d’Ivoire / Ivory Coast
1
Morocco
1
USA
1
Saudi Arabia
1
Ethiopia
1
Cameroon
1
Uganda
1
Haiti
1
Somalia
1
Iraq
1
Jordan
1
Lebanon
1
Turkey
1
Egypt
1
Chad
1
Tanzania
1
Rwanda
1
Indonesia
1
Mauritania
1
Sudan
1
Benin
1
Argentina
1
Dominican Republic
1
Namibia
1
Peru
1
Brazil
1
North Macedonia
1
Cuba
1
Ukraine
1
Colombia
1
Honduras
1
Ecuador
1
El Salvador
1
Bolivia
1
Libya
1
Guatemala
1
Madagascar
1
Mexico
1
Nicaragua
1
Chile
1
Yemen
1
East and Southern Africa
1
Western Pacific Region
1
Western and Central Europe
1
Congo-Brazzaville
1
Qatar
1
Kazakhstan
1
Vietnam
1
Tunisia
1
United Kingdom
1
Portugal
1
Belarus
1
Israel
1
Authors & Publishers
Publication Years
Category
Countries
43
Clinical Guidelines
33
Public Health
16
Pharmacy & Technologies
9
Women & Child Health
6
Capacity Building
2
Key Resources
2
Toolboxes
COVID-19
58
Rapid Response
14
Ebola
12
HIV
10
NTDs
9
NCDs
9
Pharmacy
7
Polio
6
AMR
6
Mental Health
3
Planetary Health
3
Health Financing Toolbox
3
Cholera
2
Zika
2
Conflict
1
Natural Hazards
1
Refugee
1
TB
1
Caregiver
1
WHO/CDS/CSR/EDC/99.2 Plague Manual
Epidemiology, Distribution, Surveillance and Control
Namibia guideline for submission of applications for registration of pharmaceuticals for human use in common technical document format.
This guideline is intended to provide recommendations to applicants wishing to submit applications for the registration of medicines. It represents the Medicines Control Council’s current thinking on the safety, quality and efficacy of medicines.
Selection and Use of Essential Medicines 2021
recommended
The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and fo...
Weekly epidemiological record/ Relevé épidémiologique hebdomadaire 4 AUGUST 2017, 92th YEAR / 4 AOÛT 2017, 417-436
Responding to a poliovirus event and outbreak, Part 1: General (SOPs) describes the general principles and steps to facilitate timely and effective responses to poliovirus events and outbreaks, and incorporate lessons learned from recent previous outbreak response efforts. This document summarizes r...
The main objectives of the SOPs are to: (i) establish standards and timelines for response activities; and (ii) guide national governments and GPEI partners in key support functions.
This new version of the SOPs presents overall response requirements for dealing with type 1, 2 and 3 poliovirus fo...
This WHO information note provides an updated list of recommended criteria for selecting RDTs for malaria, and highlights the performance of RDTs evaluated by the WHO malaria RDT product testing programme. It also provides an overview of additional considerations in the procurement of rapid tests.
WHO TRS N°1012.
Key updates include: (i) surveillance strategies, including cross-sectoral linking of systems and suitable diagnostics; (ii) the latest recommendations on human and animal immunization; (iii) palliative care in lowresource settings; (iv) risk assessment to guide management of bite...
Managing epidemics
recommended
Key facts about major deadly diseases.This manual provides concise and up-to-date knowledge on 15 infectious diseases that have the potential to become international threats, and tips on how to respond to each of them.
You can download an interactive version directly at the website
http://www.who....
Prepared as an outcome of ICMR Subcommittee on Multiple Myeloma | This consensus document on management of multiple myeloma summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular markers and research questions. It also i...
Prepared as an outcome of ICMR Expert Group on Immunophenotyping of Hematolymphoid Neoplasms | Coordinated by Division of Non Communicable Diseases | This document addresses on various issue related to good quality practices in laboratory work up of flow cytometric immunophenotyping and will be of u...
The goal of the strategy is to prevent seasonal influenza, control the spread of influenza from animals to humans, and prepare for the next influenza pandemic.
The new strategy is the most comprehensive and far-reaching that WHO has ever developed for influenza. It outlines a path to protect popul...
WHO’s Essential Medicines List and List of Essential Diagnostics are core guidance documents that help countries prioritize critical health products that should be widely available and affordable throughout health systems. The updated Essential Medicines List adds 23 medicines for children.
Report of the 23rd WHO Expert Committee on the selection and use of essential medicines
This executive summary reports the recommendations made by the Expert Committee for the 2021 update of the WHO Model List of Essential Medicines (EML) and the Model List of Essential Medicine for Children (EMLc)...
Annual report on global preparednessfor health emergencies
The next pandemic is not a question of if, but when—and the world is woefully unprepared, according to the first annual report from the Global Preparedness Monitoring Board. The WHO and the World Bank convened the independent group after ...
J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...
